^
Association details:
| Biomarker: | CD8 positive |
|---|---|
| Cancer: | Fibrosarcoma |
| Drug: | bempegaldesleukin (NKTR-214) (IL-2 stimulant, CD122 agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer
Excerpt:
Animals bearing bilateral subcutaneous MCA-205 fibrosarcoma or CT26 colorectal tumors were treated with NKTR-214, RT, or combination therapy...Combination therapy resulted in increased magnitude and effector function of tumor-specific CD8+ T cell responses...This data suggest that CD8+ T cells are the primary driver of the antitumor response to combination therapy (figure 1D).
DOI:
http://dx.doi.org/10.1136/jitc-2019-000464
